- Home
- MNSB vs CNTB Comparison
MNSB vs CNTB Comparison
Compare MNSB & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNSB | CNTB |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | 171 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.9M | 135.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MNSB | CNTB |
|---|---|---|
| Price | $22.78 | $2.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 28.7K | ★ 159.4K |
| Earning Date | 04-20-2026 | 08-13-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | $1.50 | N/A |
| Revenue Next Year | $3.77 | N/A |
| P/E Ratio | $12.64 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.86 | $0.75 |
| 52 Week High | $25.17 | $3.82 |
Technical Indicators
Market Signals| Indicator | MNSB | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 45.33 | 42.81 |
| Support Level | $21.85 | $2.03 |
| Resistance Level | $23.10 | $2.68 |
| Average True Range (ATR) | 0.67 | 0.18 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 36.06 | 17.55 |
Price Performance
Historical ComparisonAbout MNSB MainStreet Bancshares Inc.
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.